STABLE-MATES
Phase 3 Recruiting
272 enrolled
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 Recruiting
46 enrolled
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Phase 2/3 Recruiting
806 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
416 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
Phase NA Recruiting
3,000 enrolled
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Phase 3 Recruiting
306 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
Phase NA Recruiting
60 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Virtual Agent Feasibility in Oncology Patients (NTT Data)
Phase NA Recruiting
36 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
ARCH
Phase 3 Recruiting
390 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
BA-004
Phase NA Recruiting
2,063 enrolled
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
400 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
144 enrolled
KETO-FDG Lung
Phase NA Recruiting
30 enrolled
E-SEAL
Phase NA Recruiting
160 enrolled
DART-NK-SCLC
Phase 1/2 Recruiting
60 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
Empathic Communication Skills (ECS) Training
Phase NA Recruiting
1,232 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
CONNECTing to LungCare
Phase NA Recruiting
147 enrolled
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 Recruiting
45 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Phase 1/2 Recruiting
37 enrolled
RIB-ESPB
Phase NA Recruiting
60 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Phase 2 Recruiting
18 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
HEALS
Phase NA Recruiting
675 enrolled
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 Recruiting
710 enrolled
ADOPT-lung
Phase 3 Recruiting
290 enrolled
KANDLELIT-004
Phase 3 Recruiting
600 enrolled